Waverly Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5.21M Buy
85,970
+28,502
+50% +$1.66M 0.04% 402
2025
Q4
$3.1M Buy
57,468
+13,939
+32% +$671K 0.03% 485
2025
Q3
$1.96M Buy
43,529
+4,006
+10% +$187K 0.02% 516
2025
Q2
$1.83M Buy
39,523
+126
+0.3% +$6.18K 0.02% 509
2025
Q1
$2.4M Buy
39,397
+7,298
+23% +$425K 0.03% 440
2024
Q4
$1.82M Buy
32,099
+18,722
+140% +$1.05M 0.03% 406
2024
Q3
$692K Buy
13,377
+6
+0% +$281 0.01% 517
2024
Q2
$555K Buy
13,371
+1,011
+8% +$45.2K 0.01% 557
2024
Q1
$670K Buy
12,360
+1,316
+12% +$67K 0.02% 426
2023
Q4
$567K Buy
11,044
+559
+5% +$29.3K 0.02% 281
2023
Q3
$609K Buy
10,485
+1,078
+11% +$66.1K 0.03% 239
2023
Q2
$602K Sell
9,407
-9,806
-51% -$658K 0.03% 225
2023
Q1
$1.33M Sell
19,213
-1,229
-6% -$86.7K 0.07% 124
2022
Q4
$1.47M Buy
20,442
+10,651
+109% +$803K 0.08% 108
2022
Q3
$696K Buy
9,791
+5,328
+119% +$386K 0.05% 132
2022
Q2
$343K Sell
4,463
-122
-3% -$9.29K 0.03% 157
2022
Q1
$335K Sell
4,585
-775
-14% -$52K 0.03% 151
2021
Q4
$358K Buy
5,360
+775
+17% +$45.5K 0.03% 146
2021
Q3
$272K Buy
4,585
+55
+1% +$3.62K 0.02% 180
2021
Q2
$306K Buy
4,530
+263
+6% +$17.1K 0.03% 151
2021
Q1
$286K Buy
4,267
+639
+18% +$39.8K 0.03% 138
2020
Q4
$218K Buy
+3,628
New +$223K 0.02% 144
2020
Q3
Sell
-3,195
Closed -$202K 146
2020
Q2
$202K Buy
+3,195
New +$191K 0.03% 147
2020
Q1
Sell
-3,128
Closed -$210K 148
2019
Q4
$210K Buy
+3,128
New +$179K 0.03% 128
2018
Q4
Sell
-11,480
Closed -$713K 128
2018
Q3
$713K Buy
11,480
+6
+0.1% +$356 0.11% 100
2018
Q2
$635K Buy
11,474
+7
+0.1% +$378 0.1% 107
2018
Q1
$725K Sell
11,467
-6,236
-35% -$401K 0.12% 98
2017
Q4
$1.08M Buy
17,703
+1,089
+7% +$68.1K 0.15% 91
2017
Q3
$1.06M Sell
16,614
-373
-2% -$21.8K 0.23% 81
2017
Q2
$947K Buy
16,987
+1,883
+12% +$102K 0.24% 79
2017
Q1
$821K Buy
15,104
+11,127
+280% +$610K 0.22% 84
2016
Q4
$232K Buy
+3,977
New +$217K 0.09% 97
2016
Q1
Sell
-6,154
Closed -$423K 101
2015
Q4
$423K Buy
6,154
+5,945
+2,844% +$393K 0.18% 63
2015
Q3
$12K Hold
209
0.01% 331
2015
Q2
$14K Hold
209
0.01% 246
2015
Q1
$13K Hold
209
0.01% 233
2014
Q4
$12K Sell
209
-117
-36% -$6.6K 0.01% 271
2014
Q3
$17K Sell
326
-1,056
-76% -$52.7K 0.01% 367
2014
Q2
$67K Buy
1,382
+932
+207% +$45.9K 0.03% 197
2014
Q1
$23K Sell
450
-5,872
-93% -$312K 0.01% 297
2013
Q4
$336K Buy
6,322
+319
+5% +$16.3K 0.12% 103
2013
Q3
$278K Buy
6,003
+1
+0% +$44 0.14% 75
2013
Q2
$268K Buy
+6,002
New +$261K 0.15% 75

Other funds holding BMY

Waverly Advisors's BMY Position: Q1 2026 in Review

Waverly Advisors increased its Bristol-Myers Squibb (BMY) stake by 50% in Q1 2026, buying an estimated $1.66M and bringing the position to 85,970 shares worth $5.21M. The position accounts for 0.04% of the portfolio, ranked #402.

Waverly Advisors first reported a position in BMY in Q2 2013 and has held it in 43 quarters since. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Waverly Advisors held 85,970 shares of Bristol-Myers Squibb worth $5.21M as of Q1 2026.
  • Waverly Advisors bought 28,502 Bristol-Myers Squibb shares in Q1 2026, an estimated $1.66M.
  • Bristol-Myers Squibb made up 0.04% of Waverly Advisors's portfolio in Q1 2026, its #402 holding.
  • Waverly Advisors first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 43 quarters since.
  • 2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Waverly Advisors's 13F filing for Q1 2026, filed 15 May 2026.